Note: Descriptions are shown in the official language in which they were submitted.
CA 02682525 2009-09-30
WO 2008/119534
PCT/EP2008/002542
Production of a viable, storable worm egg suspension
The present invention relates to a purification method
for the production of viable suspensions which contain
eggs of parasitic helminths, which suspensions are
capable of development and are suitable for therapeutic
application.
The effect of parasitic infections on the activation of
their animal hosts' immune system is known (review,
D.M. McKay, Parsitology 2006, 132: 1-12). This
activation also influences the appearance and course of
diseases of the immune system. Epidemiological studies
demonstrate that autoimmune diseases occur more rarely
in regions with high worm infection rates than in
regions in which these infection rates are lower due to
better hygienic circumstances. Cytokin profiles of
patients with Crohn's disease, a chronic-inflammatory
disease of the intestine, have demonstrated that Th2
immune cells can be stimulated by helminth infections.
Crohn's disease, a Thl-dominated autoimmune disease,
can be prevented or influenced by an infection with
helminths (Summers et al., Am J Gastroenterol 2003, 98:
2034-2041). Other diseases caused by Th1 immune cells,
too, are capable of being influenced, as are gastritis
caused by Helicobacter and
autoimmune
encephalomyelitis.
Beer (Parasitology 1973, 67: 253-262) has reported as
early as in 1973 that Trichuris suis may be a suitable
nematode for achieving immunization in humans without
pathogenic infection with nematodes taking place.
Trichuris suis is closely related to Trichuris humanis
and survives in the human gastrointestinal tract, but
fails to multiply. Therapeutic measures are not
necessary during this self-limiting infection.
Infection by Trichuris suis can therefore bring about
immunization.
CA 02682525 2009-09-30
WO 2008/119534
PCT/EP2008/002542
- 2 -
R.J.S. Beer (Parasitology 1972, 65: 343-350) describes
a method for collecting and purifying worm eggs. Worm
eggs in the embryonated state are grown in a 0.2%
strength potassium dichromate solution at 32 C and
aerated daily. A similar purification method is
described in DE 10 63 115. Worm eggs are freed from any
microorganisms and viruses with the aid of hydroxyl-
radical- or oxygen-radical-producing
chemical
reactions. The so-called Fenton reaction is described
in particular. In this reaction, FeC12 is allowed to
act on H202 to give nascent oxygen, whose disinfectant
activity is exploited.
Boes et al., Veterinary Parasitology (1998), pages
181 - 190, describe the embryonation and infectivity of
eggs of the worm Ascaris suum which have been obtained
from female worms and which have been embryonated in
sulfuric acid.
Summers and coworkers (GUT 2005, 54: 87-90) also purify
T. suis eggs with a 0.2% strength dichromate solution
in phosphate buffer at pH 6-7, after previously having
embryonated the eggs for 5-6 weeks in a buffer solution
containing antibiotics (pencillin/streptomycin/ampho-
tericin B).
The use of such bacteria- and virus-destroying agents
has a series of significant disadvantages:
both when using a dichromate solution and when using a
Fenton solution, the solution must be removed after a
brief period of time so as to avoid damage to the worm
eggs. Moreover, experiments have demonstrated that
copious multiplication of microorganisms takes place
during the embryonation (3 months at 22 C - 250), which
takes place after the purification, despite this
preceding purification step, nor can the multiplication
CA 02682525 2009-09-30
WO 2008/119534
PCT/EP2008/002542
- 3 -
of microorganisms be avoided during the subsequent
storage of the embyronated eggs at 2-8 C. It is
therefore likely that, once such microorganism- and
virus-destroying agents have been removed, renewed
growth of microorganisms takes place in the T. suis egg
suspension.
Moreover, the complete removal of dichromate from the
solution is absolutely necessary. However, this
procedure is very complicated.
While the addition of antibiotics for avoiding copious
multiplication of microorganisms during the eggs'
embryonation stage, as described by Summers, prevents
copious growth of microorganisms in this stage, it is
not capable of ensuring the destruction of the
microorganisms. After antibiotics have been removed in
the subsequent purification and storage steps until
use, renewed copious growth of microorganisms is
observed.
It is an object of the present invention to prepare an
embryonated worm egg suspension which is purified from
contaminating viruses and microorganisms, in particular
bacteria, and which is capable of being stored without
growth of fungal spores and of yeasts taking place. The
methods described herein retain the capability of the
worm eggs to develop into adult worms. The worm egg
suspensions are suitable for therapeutic applications.
Surprisingly, it has been found within the scope of the
present invention that a combined purification and
preservation method is particularly suitable for
solving the above-described problem, since no toxic
substances (for example potassium dichromate, K2Cr207)
and no disinfectants are required for this method, in
contrast to the previously known methods.
CA 02682525 2013-10-08
- 4 -
During the purification method, isolated eggs of
helminths, preferably of T. suis, are incubated in an
acid solution, preferably an H2SO4 solution, at a pH of
2 for a period of 1-72 hours (see example 1). The
optimal incubation time is 2 to 8 hours, preferably
3 hours. Incubation is performed at a temperature of from
4 C to 37 C, preferably from 25 C to 35 C.
The present invention further provides a process for the
preparation of a pharmaceutical preparation for oral
administration, the pharmaceutical preparation comprising
a storable suspension of viable eggs of parasitic
helminths which are nonpathogenic to humans, wherein the
parasitic helminth is Trichuris suis, where, after the
ingestion of the suspension, a sufficient number of
helminths develops to result in a stimulation of
regulatory human T-cells, the process comprising:
(a) subjecting a suspension of the helminth eggs, in
one step, to an acid treatment at a pH of 5_ 2, for a
period of 1-72 hours at a temperature of from 4 C to
37 C; and
(b) adjusting the pH to 4 and adding a
pharmacologically acceptable preservative.
In the process for the preparation of a pharmaceutical
preparation capable of being administered orally and
comprising a storable suspension of viable eggs of
parasitic helminths which are nonpathogenic to humans and
where, upon ingestion, a sufficient number of helminths
develops to result in the stimulation of regulatory human
T-cells, the helminth egg suspension, in a first step, is
initially subjected to an acid treatment at a pH of 2.
In a further step, the pH is raised to 4,
and a
CA 02682525 2012-08
- 4a -
pharmacologically acceptable preservative is added. In
principle, it is also possible first to add the
preservative and then to carry out the acid treatment.
However, it is preferred first to carry out the acid
treatment and then to add the preservative.
The acid treatment is preferably brought about by adding
sulfuric acid. In the acid treatment, a sufficient amount
of acid to lower the pH into a range of between
approximately 0.5 and 2 is added. In a further
embodiment, the pH is lowered down to approximately 0 to
< 1. Suitable acids are hydrochloric acid, nitric acid
or, preferably, sulfuric acid. The acid treatment may
only be carried out over a relatively brief period of
time so as to avoid undue damage to the worm eggs. In
this context, there is also a relationship between acid
concentration and duration of the acid treatment. It is
preferred to lower the pH to less than 2, especially
preferably even to pH 0.6 to 0.8. The duration of the
acid treatment is from several
CA 02682525 2009-09-30
WO 2008/119534
PCT/EP2008/002542
- 5 -
minutes to a few hours, preferably 120 minutes to
360 minutes. The short-term period which is still
tolerated includes the embryonation process of the worm
eggs (3 months at 22 - 25 C)
After the acid treatment, the pH is raised back to a pH
of > 4 by addition of a suitable base, for example
NaOH. Thereafter, one or more preservatives are added,
it being possible to employ, in principle, all those
substances which are suitable for the preservation of
food stuffs or pharmaceuticals. It is preferred to
employ those preservatives which are well tolerated
precisely by patients with Crohn's disease.
The preservative is preferably selected from the group
consisting of sorbic acid, benzoic acid, salts of these
acids, parabenzoic acid esters, p-hydroxybenzoic acid
esters, propylene glycol, or combinations of these
preservatives.
It is especially preferable to employ one or more of
the preservatives selected from the group consisting of
sorbic acid at a concentration of from 0.01 to
0.2%, in particular from 0.1 to 0.2%,
benzoic acid at a concentration of from 0.1 to
0.3%,
p-hydroxy-benzoic acid esters at a concentration
of from 0.02 to 0.3% by weight,
propylene glycol at a concentration of from 5 to
20% by weight,
or a combination of the abovementioned
preservatives in the abovementioned concentration
ranges.
As an alternative to strong acids, weaker acidic
solutions with addition of the abovementioned
preservatives, preferably sorbic acid and its salts,
are also suitable for the rapid inactivation of
CA 02682525 2013-08
- 6 -
microorganisms and viruses. However, the advantage of
using these solutions over using strong acids is that the
worm eggs can be purified, embryonated (for 3 months at
22 - 25 C), stored and used for patients in a single
medium, owing to the less acidic pH. This long-term
treatment has no adverse effect on the viability of the
worm eggs (see example 5). This mild method uses
preservative-containing media with a pH of 1,
preferably 2, and results in no limitations with regard
to the microbiological purity of the worm egg
suspensions.
The resulting preservative-containing suspensions with
embryonated worm eggs are suitable for use in patients as
a drink. If appropriate, further pharmaceutically
acceptable additives such as colorants, flavorings or
thickeners may be added to these worm egg suspensions.
The invention therefore relates to pharmaceutical
preparations for oral administration, comprising a
storable suspension of viable eggs of parasitic helminths
which are nonpathogenic to humans, in particular T. suis,
where, after the ingestion of the suspension, a
sufficient number of helminth develops to result in a
stimulation of regulatory T-cells, and where the
suspension comprises fewer than 1000 colony-forming
(cfu = colony-forming unit) microorganisms per ml of
suspension. Preferably, the pharmaceutical preparation
for oral administration contains fewer than 100 colony-
forming units of microorganisms per ml of suspension.
Especially preferably, the pharmaceutical preparation for
administration contains fewer than 10 colony-forming
units of microorganisms per ml of suspension. The number
of colony-forming units is determined with the aid of
customary microbiological methods.
CA 02682525 2014-08-14
- 6a -
The present invention further provides a pharmaceutical
preparation for oral administration, comprising a
storable suspension of viable eggs of parasitic helminths
which are nonpathogenic to humans, wherein the parasitic
helminth is Trichuris suis, where, after the ingestion of
the suspension, a sufficient number of helminths develops
to result in a stimulation of regulatory T-cells, the
suspension comprising fewer than 1000 colony-forming
microorganisms per ml of suspension. In an embodiment,
the preparation is prepared by a process defined herein.
In the present context, microorganisms are understood
CA 02682525 2013-10-08
- 7 -
as meaning bacteria, viruses, fungi, yeasts and
protozoans and no such microorganisms which might have
disadvantageous health effects may be present.
The method according to the invention makes it possible
to provide the suspension of storable eggs of parasitic
helminths which are nonpathogenic to humans in a form in
which they are suitable for
pharmaceutical
administration. The treatment according to the invention
firstly destroys contaminating microorganisms, in
particular bacteria, but also fungi, viruses and, if
appropriate, protozoans, to such an extent that the
preparation is suitable for pharmaceutical application.
Secondly, however, the treatment is mild enough for the
worm eggs to retain their ability of growing, once
ingested, in the patient's intestines so as to bring
about the desired stimulation of the immune system.
The preparations according to the invention are
particularly suitable for the treatment of various
inflammatory diseases of the intestine, especially
chronic-inflammatory diseases of the intestine. The
preparations can be employed in a particularly
advantageous manner for the treatment of inflammatory
diseases of the intestine referred to as Crohn's disease.
The present invention further provides a use of a
storable suspension of eggs of parasitic helminths,
wherein the parasitic helminth is Trichuris suis,
prepared by a process as defined herein, for making a
pharmaceutical preparation for the treatment of an
inflammatory disease of the intestine.
The present invention further provides a use of a
storable suspension of eggs of parasitic helminths,
CA 02682525 2014-08-14
- 7a -
wherein the parasitic helminth is Trichuris suis,
prepared by a process as defined herein, for the
treatment of an inflammatory disease of the intestine.
The present invention further provides a storable
suspension of eggs of parasitic helminths, wherein the
parasitic helminth is Trichuris suis, prepared by a
process defined herein, for making a pharmaceutical
preparation for the treatment of an inflammatory disease
of the intestine.
Example 1: depletion of microorganisms in a suspension of
T. suis eggs:
The microbial count in a Trichuris suis egg suspension
(TSO) in phosphate buffer (pH 7) at a concentration of
2400 eggs/ml was determined as specified in the DAB
(German Pharmacopoeia, section 2.6.12, last updated with
the 24th Supplement in 2006). A microbial count status of
190 000 cfu/ml was found. This suspension was then
rebuffered to pH 2 in dilute H2SO4 solution. After
CA 02682525 2009-09-30
WO 2008/119534
PCT/EP2008/002542
- 8 -
storage for 3 h at 30 C, the microbial count had been
reduced to < 20 cfu/ml.
The quality of the process presented was then checked.
To this end, defined test strains of bacteria, yeast
and fungi were used as specified in the German
Pharmacopoeia (DAB). Examples 2a, 2b and 2c show the
results of this test.
Example 2: determination of the microbial count
a. A nutrient suspension as
specified in
DAB 2.6.13 was inoculated with the sporulating
and nonsporulating test bacteria detailed in
table 1. Then, the mixture was rebuffered to
pH 2 using a dilute H2SO4 solution and stored
for 6 h at 30 C. The subsequent determination
of the microbial count gave the data shown in
table 1.
Table 1
Microorganism To H2SO4 pH 2 after 6 h
Clostridium sporog. 8 000 000 < 10
Bacillus subtilis 1 400 000 20*
Escherichia coli 130 000 < 10
Staphylococus aureus 800 000 < 10
Salmonella typhymurium 250 000 < 10
* By extending the acid treatment to approximately 6 to
10 hours, it was possible to reduce the number of
colony-forming units to less than 10.
b. A nutrient suspension as
specified in
DAB 2.6.13 was inoculated with the test yeasts
detailed in table 2. Then, the mixture was
rebuffered to pH 2 or pH 1 using a dilute H2SO4
solution and stored for 3 h or 48 h at 25 C.
CA 02682525 2009-09-30
WO 2008/119534
PCT/EP2008/002542
- 9 -
The subsequent determination gave the data
shown in table 2.
Table 2
Microorganism To T3h T48h T3h T4811
H2SO4 pH 2 H2SO4 pH 1
Saccharomyces 470 000 380 000 220 000 39 000 40*
cer.
Candida 690 000 380 000 32 000 26 000 < 10
albicans
* By extending the acid treatment to 72 hours, it was
possible to reduce the cfu to 5.
C. A nutrient suspension as specified in
DAB 2.6.13 was inoculated with the test molds
detailed in table 3. Then, the mixture was
rebuffered to pH 2, pH 1 and pH 0 using a
dilute H2SO4 solution and stored for 3 h or
48 h at 25 C. The subsequent determination
gave the data shown in table 3.
Table 3
Microorganism To T3h T48h T3h T48h T3h
T48h
H2SO4 pH 2 H2SO4 pH 1 H2SO4
pH 0
Penicillium 490 000 90 000 32 000 39 000 14 000 70 <
10
brevicomp.
Aspergillus 800
000 370 000 700 000 500 000 500 000 50 < 10
niger
If the cfu of certain microorganisms has not been
reduced sufficiently by the acid treatment, the
duration of the acid treatment was suitably extended to
up to 72 hours.
CA 02682525 2009-09-30
WO 2008/119534
PCT/EP2008/002542
- 10 -
Examples 1 and 2 a-c demonstrate that, after a brief
period of time, bacteria are destroyed efficiently by a
dilute H2SO4 solution of pH 2. Yeasts and fungi require
either a longer incubation period or more acidic
pH values in order to be destroyed efficiently.
Surprisingly, the above-described purification steps
are also suitable for the preparation of a virus-free
T. suis egg suspension.
Example 3: virus depletion:
Inactivation of murine leukemia virus (MuLV),
pseudorabies virus (PRV), porcine parvovirus (PPV) and
feline calicivirus (FCV) in the preparation of a
Trichuris suis egg suspension (TSO). The viruses
employed are model viruses.
The virus titers in the inoculated samples were
determined by end-point titration. In this method,
which is known per se, dilute samples are applied to
microtiter plates containing indicator cells which are
readily identifiable. After the infection of the
indicator cells with the virus-containing samples, the
cell morphology changes as the result of cell lysis.
This cell lysis can be measured readily under the
microscope.
The enveloped and naked test viruses were added in high
concentration to an 0.01 N H2SO4 solution (pH 2, 30 C)
which additionally contains TSO. After 10 min, 3 h and
72 h, the viral activity was determined. After 10 min,
the enveloped viruses PRV and MuLV were no longer
infectious, and the naked viruses FCV and PPV were no
longer infectious after 3 h. The use of a parallel
sample neutralized with 1 N NaOH showed that all 4
viruses retained their virulence even after incubation
for 3 h. Due to the cytotoxicity of a 0.2% strength
CA 02682525 2009-09-30
WO 2008/119534
PCT/EP2008/002542
- 11 -
potassium dichromate solution in 0.01 N sulfuric acid,
it was not possible to test this solution by way of
comparison.
A pronounced reduction of fungi and yeasts too was only
possible by prolonged incubation and lowering the pH to
a value of 0, preferably < 1 (see example 2, tables 2
and 3). This purification method in highly acidic
medium, which method is novel, has the disadvantage
that the viability of a worm egg suspension is
adversely affected.
As the second feature of the present invention, it has
now been found, surprisingly, that the addition of
orally acceptable chemicals used for preservation
purposes result in obtaining the embryonation
coefficient. The embryonation coefficient is an
unambiguous marker for the viability of worm egg
suspensions. Moreover, the use of preservatives made it
possible to inactivate contaminating microorganisms
even at pH 4. Orally acceptable preservatives which
have proved to be preferred are benzoic acid, sorbic
acid, their salts, and propylene glycol (see example
4 a - e).
Only the addition of preservatives makes possible the
use of considerably less acidic media, that is media
which are better tolerated by the worm eggs. In this
manner, the worm eggs can be purified, embryonated,
stored and used for the patient in a single medium. A
medium for long-term application is therefore
available. A possible recontamination of the TSO
suspensions with fresh microorganisms can be prevented
by using dilute acids and the addition of
preservatives. The growth of fresh microorganisms is
avoided by the above-described combined method of
inactivating and preserving of TS0 suspension. Thus,
this extremely gentle method has clear advantages over
CA 02682525 2009-09-30
WO 2008/119534
PCT/EP2008/002542
- 12 -
the method based on the use of strong acids.
Example 4: determination of the colony number of
various microorganisms
Raising the pH from pH 2 to pH 4 and addition of
preservatives
Experimental conditions for examples 4a to 4e:
The test samples contained in each case 10 000 TSO/m1
( 10%) in phosphate buffer at pH 4 and either 0.2%
benzoic acid, 0.1% sorbic acid or 15% propylene glycol.
The following microorganisms were added to the test
samples:
- Aspergillus niger in the form of an individual
microorganism
- Pseudomonas aruginosa, Staphylococcus aureus,
Candida albicans and Escherichia coil in
combination.
The incubation temperature was 25 C. The test plates
were evaluated after 1 to 7 days. The following results
were obtained:
4a Psuedomonas aeruginosa
Preservative T 0 (cfu/ml) T id (cfu/ml) T 7d (cfu/ml)
Benzoic acid 0.2% 180 000 < 10 < 10
Sorbic acid 0.1% 180 000 30 < 10
Propylene glycol 15% 180 000 10 < 10
4 b Staphylococcus aureus
Preservative T 0 (cfu/ml) T ld (cfu/ml) T 7d (cfu/ml)
Benzoic acid 0.2% 130 000 < 10 < 10
Sorbic acid 0.1% 130 000 240 < 10
Propylene glycol 15% 130 000 14 000 < 10
CA 02682525 2009-09-30
WO 2008/119534
PCT/EP2008/002542
,
- 13 -
4 c Escherichia coil
Preservative T 0 (cfu/ml) T id (cfu/ml) T 7d (cfu/ml)
Benzoic acid 0.2% 140 000 < 10 < 10
Sorbic acid 0.1% 140 000 490 < 10
Propylene glycol 15% 140 000 7100 < 10
4 d Candida albicans
Preservative T 0 (cfu/ml) T id (cfu/ml) T 7d (cfu/ml)
Benzoic acid 0.2% 240 000 < 10 < 10
Sorbic acid 0.1% 240 000 190 < 10
Propylene glycol 15% 240 000 8600 30
4 e Aspergillus niger
Preservative T 0 (cfu/ml) T id (cfu/ml) T 7d (cfu/ml)
Benzoic acid 0.2% 120 000 90 < 10
Sorbic acid 0.1% 120 000 20 000 < 10
Propylene glycol 15% 120 000 30 000 9000
When fungal contamination is severe, it is preferred to
employ sorbic acid, benzoic acid
and/or
p-hydroxybenzoic acid esters, or propylene glycol is
employed as a combination with these preservatives.
A further advantage of the combined inactivation of
microorganisms by means of dilute acids and the use of
preservatives is that recontamination with fresh
microorganisms, which is possible, can be prevented
during the further use of the TS0 suspension. The
growth of fresh microorganisms is avoided by the above-
described combined method of inactivating and
preserving a TS0 suspension.
The preparation for the further production and use in
patients requires that the pH be raised to a range of
pH 2 - 7, preferably pH 4 - 6. Again, this third step
requires the addition of suitable preservatives.
CA 02682525 2009-09-30
WO 2008/119534
PCT/EP2008/002542
- 14 -
Preservatives which may be used must be suitable for
oral administration. Those which have proved to be
suitable for this purpose are sorbic acid at a
concentration of 0.1 - 0.2%,
benzoic acid at a
concentration of 0.1 - 0.3%, p-hydroxybenzoic acid
ester at concentrations of 0.02 - 0.3% or propylene
glycol as a 5 - 20% strength aqueous solution. Mixtures
of the abovementioned preservatives are also suitable.
Surprisingly, it has been found that the viability of
the worm egg suspension is not adversely affected by
this purification method.
Example 5: viability of the worm eggs
Unembryonated worm eggs at a concentration of 40 000
eggs/ml were suspended in different media and
embryonated (22 - 250C). After an incubation time of 60
and 90 days, the individual suspensions were viewed
under the microscope, and the embryonation coefficient
was calculated based on the total number of worm eggs
and the number of morphologically intact and
embryonated worm eggs. The embryonation coefficient
(EC) is an indicator for the viability of the worm
eggs. At the beginning of the embryonation, only
unembryonated worm eggs are present, so that the
coefficient is zero. It increases during the
embryonation period and, at the incubation conditions
chosen, reaches its maximum from day 60 onwards. As a
rule, values around 90% are obtained.
Suspension medium EC Day
0 EC Day 60 EC Day 90
Sulfuric acid pH 1 + 0.01% 0 0.91 0.91
potassium sorbate
Sulfuric acid pH 1 + 0.07% 0 0.93 0.91
potassium sorbate
Sulfuric acid pH 0.8 0 0.94 0.90
Sulfuric acid pH 0.5 0 0.92 0.77
CA 02682525 2009-09-30
WO 2008/119534
PCT/EP2008/002542
- 15 -
After an embryonation period of 60 days, a proportion
of over 90% embryonated eggs was found for all media.
While the preservative-containing media independently
of the preservative concentration showed no decrease in
the embryonation coefficient after a further 30 days, a
drop in the proportion of embryonated worm eggs can
already be observed at sulfuric acid pH 0.5. The
addition of orally tolerated preservatives, preferably
sorbic acid and its salts, therefore permits the use of
pH values which are harmless to the worm eggs. This
method can therefore be employed for producing a
preparation which is suitable for stable storage
(gentle method).
The preparation for the further production requires
that the pH be raised to a range of pH 2 - 7,
preferably pH 4 - 6, and that suitable preservatives be
added. The preservatives to be used must be suitable
for oral administration. Those which have proved to be
suitable for this purpose are sorbic acid at a
concentration of 0.1 - 0.2%,
benzoic acid at a
concentration of 0.1 - 0.3%, or propylene glycol as a
5 - 20% strength aqueous solution. Mixtures of the
abovementioned preservatives are also suitable.
